3217-93-4

Usage

Synthesis Reference(s)

Tetrahedron, 46, p. 7443, 1990 DOI: 10.1016/S0040-4020(01)89059-1

InChI:InChI=1/C8H11NO/c10-9-7-6-8-4-2-1-3-5-8/h1-5,9-10H,6-7H2

Upstream product

• 7028-48-0 Phenylacetaldehyde oxime 
• 64-04-0 phenethylamine 
• 6388-72-3 2-(4-methoxyphenyl)oxirane 
• 67287-36-9 2-(2-chloro-3,4-dimethoxyphenyl)ethylamine 
• 122-78-1 phenylacetaldehyde 
• 103-63-9 1-phenyl-2-bromoethane 
• 17376-04-4 2-phenethyl iodide 
• 100-42-5 styrene 
• 2783-26-8 o-methylstyrene oxide 
• 3591-82-0 2-phenylethylaminoacetonitrile 
• 5153-67-3 nitrostyrene 
• 6125-24-2 2-Phenylnitroethane 
• 300843-71-4 C₁₀H₁₀N₂O 
• 102-96-5 (2-nitroethenyl)benzene 

Downstream Products

• 156025-65-9 N-hydroxy-N-(2-phenylethyl)-2-furancarboxamide 
• 143620-64-8 (Z)-1-(4-Fluoro-phenyl)-3-(hydroxy-phenethyl-amino)-propenone 
• 156025-64-8 N-hydroxy-N-(2-phenylethyl)benzamide 
• 156025-66-0 N-hydroxy-N-(2-phenylethyl)-3-methylbutanamide 
• 53950-66-6 N-β-Phenethyl-N-formylhydroxylamin 
• 851228-84-7 C₄₃H₇₁NO₃Si₂ 
• 5460-60-6 N-phenethyl-2-phenylacetamide 
• 1226764-22-2 C₅₁H₈₇NO₄Si₃ 
• 1226764-21-1 (23R,25S)-2α-methyl-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(2-phenethyl) 
• 1226764-19-7 (23R,25R)-2α-methyl-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(2-phenethyl) 
• 1226764-18-6 (23S,25S)-2α-methyl-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(2-phenethyl) 
• 1226764-20-0 (23S,25R)-2α-methyl-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(2-phenethyl) 
• 1226764-23-3 C₅₉H₁₀₅NO₅Si₄ 

Relevant academic research and scientific papers

Ultrasonic promoted synthesis of Ag nanoparticle decorated thiourea-functionalized magnetic hydroxyapatite: A robust inorganic-organic hybrid nanocatalyst for oxidation and reduction reactions

In this research, ultrasonic synthesis is applied for the fabrication of a novel catalyst, based on immobilization of silver nanoparticles (AgNPs) on thiourea functionalized magnetic hydroxyapatite. A recoverable Ag nano-catalyst is constructed by decoration of AgNPs on the surface of thiourea modified magnetic hydroxyapatite. Magnetic hydroxyapatite is used as an organic-inorganic hybrid support for the catalyst. The organic-inorganic hybrid support is prepared by co-precipitation, followed by its surface modification through covalent functionalization of 1-(3,5-bis(trifluoromethyl)phenyl)-3-propyl)thiourea. The fabricated catalyst has been characterized by transmission electron microscopy (TEM), scanning electron microscopy (SEM), powder X-ray diffraction (XRD), nuclear magnetic resonance (NMR), Fourier-transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA) and Brunauer-Emmett-Teller (BET) analysis. The nanoparticles are mostly tubular in shape and their particle sizes are smaller than 100 nm. This nanocatalyst shows efficient and robust catalytic activity in different reactions, including selective reduction of 4-nitrophenol (4NP) and oxidation of primary amines by applying NaBH4and urea hydrogen peroxide (UHP) as reagents, respectively. The catalyst shows good reusability in 10 sequential reaction runs.

Chemoselective Synthesis of Amines from Ammonium Hydroxide and Hydroxylamine in Continuous Flow

The chemoselective amination of alkyl bromides and chlorides with aqueous ammonia and hydroxylamine was achieved in continuous flow to produce primary ammonium salts and hydroxylamines in high yields. An in-line workup was designed to isolate the corresponding primary amine, which was also telescoped in further reactions, such as acylation and Paal-Knorr pyrrole synthesis. Monosubstituted epoxides are also compatible with the reaction conditions.

Primary hydroxylamines and uses thereof

The present invention relates to primary hydroxylamines, to pharmaceutical compositions comprising them, to their use in the treatment and/or prevention of bacterial infections and to their use in the prevention of formation or reduction of formed biofilm

VITAMIN D3 LACTAM DERIVATIVE

Compound represented by formula (1) or a pharmaceutically acceptable solvate thereof, useful for treating or preventing Paget's disease of bone, hypercalcaemia, osteoporosis or asthma. (1) R1 represents a C1-C6 alkyl group

Intermolecular Cope-type hydroamination of alkenes and alkynes using hydroxylamines

The development of the Cope-type hydroamination as a method for the metal- and acid-free intermolecular hydroamination of hydroxylamines with alkenes and alkynes is described. Aqueous hydroxylamine reacts efficiently with alkynes in a Markovnikov fashion to give oximes and with strained alkenes to give N-alkylhydroxylamines, while unstrained alkenes are more challenging. N-Alkylhydroxy-lamines also display similar reactivity with strained alkenes and give modest to good yields with vinylarenes. Electron-rich vinylarenes lead to branched products while electron-deficient vinylarenes give linear products. A beneficial additive effect is observed with sodium cyanoborohydride, the extent of which is dependent on the structure of the hydroxylamine. The reaction conditions are found to be compatible with common protecting groups, free OH and NH bonds, as well as bromoarenes. Both experimental and theoretical results suggest the proton transfer step of the N-oxide intermediate is of vital importance in the intermolecular reactions of alkenes. Details are disclosed concerning optimization, reaction scope, limitations, and theoretical analysis by DFT, which includes a detailed molecular orbital description for the concerted hydroamination process and an exhaustive set of calculated potential energy surfaces for the reactions of various alkenes, alkynes, and hydroxylamines.

Intermolecular cope-type hydroamination of alkenes and alkynes

(Chemical Equation Presented) Keep it simple! Intermolecular hydroamination can be achieved simply upon heating alkynes and alkenes with aqueous hydroxylamine. Alkynes react to afford oximes in good to excellent yields, and the formation of Markovnikov products is favored. A mechanism involving Cope-type hydroamination followed by bimolecular proton transfer is suggested and supported by DFT studies.

Palladium-catalyzed silane/siloxane reductions in the one-pot conversion of nitro compounds into their amines, hydroxylamines, amides, sulfonamides, and carbamates

A combination of palladium(II) acetate, aqueous potassium fluoride, and polymethylhydrosiloxane (PMHS) facilitates the room-temperature reduction of aromatic nitro compounds to anilines. These reactions tend to be quick (30 min), high-yielding, and tolerate a range of other functional groups. Replacement of PMHS/KF with triethylsilane allows for the reduction of aliphatic nitro compounds to their corresponding hydroxylamines. Depending on the substrate, both conditions can allow for the in situ conversion of the product amines into amides, sulfonamides, and carbamates. Georg Thieme Verlag Stuttgart.

Practical synthesis and evaluation of the biological activities of 1α,25-dihydroxyvitamin D3 antagonists, 1α,25- dihydroxyvitamin D3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis

A practical synthetic route to novel vitamin D antagonists of DLAM (1α,25-dihydroxyvitamin D3-26,23-lactam) was developed from vitamin D2 via the 1,3-dipolar cycloaddition reaction as a key step. Six DLAM derivatives (24 compounds) w

Vitamin D3 lactam derivative

Compounds expressed by the following formula (1) or pharmaceutically permissible solvate thereof which is effective for treating Paget's disease of bone, hypercalcemia or osteoporosis. In the formula, R1 is a C2-C10 alkyl

Pd-catalyzed silicon hydride reductions of aromatic and aliphatic nitro groups

(Chemical Equation Presented) Room-temperature reduction of aromatic nitro groups to amines can be accomplished in high yield, with wide functional group tolerance and short reaction times (30 min) using a combination of palladium(II) acetate, aqueous potassium fluoride, and polymethylhydrosiloxane (PMHS). Replacing PMHS/KF with triethylsilane allows aliphatic nitro groups to be reduced to their hydroxylamines.